[RESEARCH BLOG] · 2026-10-08
Monopar Therapeutics Inc. (MNPR) – Exhaustion‑Driven Sell Signal Amid Crisis‑Mode Market Regime
By Pierre Brunelle · Founder & Research Lead
Monopar Therapeutics (NASDAQ: MNPR) closed at $83.78, up 5.29 % on 2026‑10‑07 (Wednesday, US session). The LOPJLB signal engine now flags a SELL directional bias with a ‑5 score, situating the stock in a CRISIS market regime.
Monopar’s recent corporate disclosures have centered on a series of operational and regulatory milestones:
- 2026‑08‑12 – Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
- 2026‑08‑13 – Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More
- 2026‑08‑14 – Monopar announced the appointment of Jeffrey D. Kent, M.D. as Executive Vice President and Head of Medical Affairs (see below).
- 2026‑08‑18 – Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For ‘Strong Buy’
- 2026‑08‑19 – Monopar Appoints Jeffrey D. Kent, M.D.
- 2026‑07‑20 – Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
- 2026‑07‑22 – Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
- 2026‑08‑24 – Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head‑To‑Head Contrast
These announcements, while operationally positive, have not yet translated into improved profitability metrics. Monopar remains a loss‑making, clinical‑stage biotech with a market capitalization of $533.0 M. The firm’s trailing twelve‑month (TTM) price‑to‑earnings (P/E) ratio sits at ‑34.0, reflecting negative earnings, while the enterprise‑value‑to‑EBITDA multiple is ‑25.97, also indicating negative EBITDA. The price‑to‑book (P/B) ratio stands at 5.19, suggesting the market values the company at over five times its book equity, despite a debt‑to‑equity (D/E) ratio of only 0.08. Analyst consensus remains bullish, with a Buy recommendation and a median price target of $126.00, implying a potential upside of roughly 50 % from the current level.
Fundamentals and Valuation
Monopar’s financial profile is dominated by persistent operating deficits and negligible margins. Gross, operating, and net profit margins are all reported at 0.00 %, a direct consequence of ongoing research and development (R&D) expenditures that outpace any revenue generation. The company’s return on invested capital (ROIC) is ‑7.85 %, while return on equity (ROE) and return on assets (ROA) are ‑13.08 % and ‑13.22 %, respectively, underscoring the capital‑intensive nature of its pipeline.
Revenue remains effectively nil, and cash flow from operations continues to be negative. The most recent free‑cash‑flow (FCF) figures, extracted from the historical data set, show a deepening cash outflow:
- 2020: –$4.66 M
- 2021: –$7.32 M
- 2022: –$7.23 M
- 2023: –$7.86 M
- 2024: –$6.40 M
- 2025: –$12.20 M
Earnings per share (EPS) have trended more negative each year, moving from ‑$0.58 in 2020 to ‑$1.85 in 2025. The corresponding price‑to‑earnings multiples have swung from ‑53.19 in 2020 to ‑35.28 in 2025, reflecting a modest improvement in the denominator but still indicating deep losses. The company’s discounted‑cash‑flow (DCF) valuation component is reported at 995.4 %, a figure that suggests the DCF model assigns a valuation many times higher than the current market price—a discrepancy that likely stems from optimistic assumptions about future product approvals and commercial uptake.
Below is a concise snapshot of Monopar’s current valuation metrics:
| Metric | Value |
|---|---|
| P/E (TTM) | –34.0 |
| P/B | 5.19 |
| EV/EBITDA | –25.97 |
| D/E | 0.08 |
| Analyst Target | $126.0 |
| Analyst Recommendation | Buy |
The valuation picture is further complicated by the firm’s % of DCF figure of 995.4 %, indicating that, according to the internal DCF model, the intrinsic value is nearly ten times the market price. While such a gap can be attractive to speculative investors, the underlying assumptions—particularly the timing of regulatory approvals for ALXN1840 and the commercial success of MNPR‑101—remain highly uncertain.
Historical Performance Context
Monopar’s historical financial trajectory illustrates a pattern of deepening losses despite incremental progress in its pipeline. EPS deteriorated from ‑$0.58 (2020) to ‑$1.85 (2025), while free cash flow deficits widened, peaking at ‑$12.20 M in 2025. The company’s ROE swung from a severe ‑40.18 % in 2020 to ‑9.95 % in 2025, suggesting a modest improvement in equity efficiency, yet still far below breakeven. ROA followed a similar trajectory, moving from ‑37.37 % to ‑9.75 % over the same period. These trends highlight the capital‑intensive nature of biotech development and the difficulty of translating R&D milestones into profitable operations.
ETF Ownership
Monopar’s institutional ownership is relatively concentrated. The stock is held by a single exchange‑traded fund, BBC, which accounts for 0.97 % of the float and is ranked #17 among the fund’s holdings. While the absolute exposure is modest, the presence of an ETF holder can introduce a layer of liquidity and may influence short‑term price dynamics, especially in a crisis‑mode market environment where ETFs often rebalance positions rapidly.
| ETF | Weight % |
|---|---|
| BBC | 0.97 % |
LOPJLB Signal Read
The LOPJLB engine currently assigns a SELL directional signal to MNPR, reflecting a ‑5 composite score. The market regime is classified as CRISIS, a condition that typically amplifies downside risk and reduces the effectiveness of growth‑oriented catalysts. The composite performance (PERF) score of 10.50 and quality (FUND) score of 19.00 place Monopar in the lower‑mid range of the LOPJLB quality spectrum. The stock’s value, growth, and GARP scores are 8.00, 47.00, and 6.00, respectively, indicating that growth considerations dominate the internal scoring, but the overall archetype is labeled Balanced.
Investors seeking a deeper dive into the technical overlays that underpin this signal—such as the exhaustion flag, EMA crossovers, and momentum metrics—should consult the interactive chart above on the Monopar stock page. The full methodology, including the construction of the directional signal and market‑regime classification, is detailed in LOPJLB’s methodology guide: https://www.lopjlb.com/methodology.
Closing Remarks
Monopar Therapeutics continues to pursue a high‑risk, high‑reward development strategy centered on ALXN1840 and the radiolabeled antibody MNPR‑101. While recent corporate actions—executive appointments, regulatory filings, and board expansions—signal operational momentum, the company’s financial fundamentals remain deeply negative, and the LOPJLB signal framework flags a pronounced downside bias in a crisis‑type market environment.
For a full data set, detailed charting, and ongoing updates, visit the dedicated Monopar page at https://www.lopjlb.com/stock/MNPR. Historical earnings releases and call transcripts (when available) can be accessed at https://www.lopjlb.com/stock/MNPR/earnings.md. To explore additional candidates that meet similar exhaustion or crisis‑regime criteria, use the LOPJLB screener at https://www.lopjlb.com/screener.
The content above is for informational and research purposes only and does not constitute investment advice or a recommendation to buy or sell any securities.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.